Read and Review our +3,000 Scientific Articles and +2,560 Clicks from NIH – Follow pharmaceuticalintelligence.com by e-Mail | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

« Cancer Signaling Pathways and Tumor Progression: Images of Biological Processes in the Voice of a Pathologist Cancer Expert

SpaceX founder Elon Musk files with government to provide Internet service from space »

Read and Review our +3,000 Scientific Articles and +2,560 Clicks from NIH – Follow pharmaceuticalintelligence.com by e-Mail

June 9, 2015 by 2012pharmaceutical

Read and Review our +3,000 Scientific Articles and +2,560 Clicks from NIH – Follow pharmaceuticalintelligence.com by e-Mail

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

Our Team

http://pharmaceuticalintelligence.com/contributors-biographies/

Curation Methodology for Scientific Findings

http://pharmaceuticalintelligence.com/2014/07/30/the-methodology-of-curation-for-scientific-research-findings/

+ 666,666 VIEWS of our Open Access Online Journal

http://www.pharmaceuticalIntelligence.com

is a scientific, medical and business, multi-expert authoring environment for information syndication in several domains of Life Sciences, Medicine, Pharmaceutical and Healthcare Industries, BioMedicine, Medical Technologies & Devices. Scientific critical interpretations and original articles are written by PhDs, MDs, MD/PhDs, PharmDs, Technical MBAs as Experts, Authors, Writers (EAWs) on an Equity Sharing basis.

BioMed e-Books e-Series

http://pharmaceuticalintelligence.com/biomed-e-books/

BioMed e-Books and related opportunities for Targeted Therapy written by Experts, Authors, Writers. The results of Original Research are gaining value added for the e-Reader by the Methodology of Curation. The e-Book’s articles have been published on the Open Access Online Scientific Journal, since April 2012. All new articles on this subject, will continue to be incorporated, as published with periodical updates.

Insert Adam’s four graphs HERE

website STAT graphs

Scientific Journal Site Statistics

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

07/29/2013 217,356 1,138 1,389 705
12/01/2013 287,645 1,428 1,676 828
02/09/2014 325,039 1,665 1,793 892
03/05/2014 338,958 1,717 1,830 965
03/21/2014 347,667 1,750 1,838 974

03/31/2014 352,683 1,768 1,869 991

05/12/2014 373.696 1,878 1,944 1,035

06/18/2014 393,111 1,992 1,982 1,087

7/27/2014 418,570 2,098 2.050 1,124

9/2/2014 444,222 2,226 2,104 1,170

10/9/2014 471,117 2,337 2,147 1,216

11/4/2014 492,736 2,471 2,194 1,234

2/15/2015 572,027 2,727 2,358 1,345

3/10/2015 591,520 2,808 2,373 1,369

6/7/2015 661,215 3,007 2,562 1,535

e-Books in the BioMedicine e-Series

Series A: e-Books on Cardiovascular Diseases

Content Consultant: Justin D Pearlman, MD, PhD, FACC

Volume One: Perspectives on Nitric Oxide

Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Aviral Vatsa, PhD and Content Consultant: Stephen J Williams, PhD

available on Kindle Store @ Amazon.com

http://www.amazon.com/dp/B00DINFFYC

Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation

Curators: Justin D Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP, Aviva Lev-Ari, PhD, RN

Causes
Risks and Biomarkers
Therapeutic Implications

Volume Three: Etiologies of CVD: Epigenetics, Genetics & Genomics

Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Causes
Risks and Biomarkers
Therapeutic Implications

Volume Four: Therapeutic Promise: CVD, Regenerative & Translational Medicine

Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Causes
Risks and Biomarkers
Therapeutic Implications

Volume Five: Pharmaco-Therapies for CVD

Curators: Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

Causes
Risks and Biomarkers
Therapeutic Implications

Volume Six: Interventional Cardiology, Cardiac Surgery and Cardiovascular Imaging for Disease Diagnosis and Guidance of Treatment

Curators: Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

Causes
Risks and Biomarkers
Therapeutic Implications

Series B: e-Books on Genomics & Medicine

Content Consultant: Larry H Bernstein, MD, FCAP

Volume 1: Genomics and Individualized Medicine

Sr. Editor: Stephen J Williams, PhD

Editors: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

Volume 2: Methodological Breakthroughs in NGS

Editor: Marcus Feldman, PhD, Prof. of Genetics, Stanford University

Volume 3: Institutional Leadership in Genomics

Editors: Marcus Feldman, PhD and Aviva Lev-Ari, PhD, RN

Series C: e-Books on Cancer & Oncology

Content Consultant: Larry H Bernstein, MD, FCAP

Volume 1: Cancer and Genomics

Sr. Editor: Stephen J Williams, PhD

Editors: Ritu Saxena, PhD, Tilda Barliya, PhD

Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

Author, Curator and Editor: Larry H Bernstein, MD, FCAP

Guest Authors: Stephen J Williams, PhD, Dror Nir, PhD and Tilda Barliya, PhD, Demet Sag, PhD, Raphael Nir, PhD, Michael Briggs, PhD

Volume 3: Cancer Patients’ Resources on Therapies

Sr. Editor: TBA

Series D: e-Books on BioMedicine

Volume 1: Metabolic Genomics & Pharmaceutics

Author, Curator and Editor: Larry H Bernstein, MD, FCAP

Volume 2: Infectious Diseases

Editor: TBA

Volume 3: Immunology and Therapeutics

Editor: TBA

Series E: Titles in the Strategic Plan for 2015

Volume 1: The Patient’s Voice: Personal Experience with Invasive Medical Procedures

Editor: TBA

Volume 2: Interviews with Scientific Leaders

Editor: TBA

Volume 3: Milestones in Physiology & Discoveries in Medicine and Genomics

Author, Curator and Editor: Larry H Bernstein, MD, FCAP

Posted in Curation | 1 Comment

One Response

on June 10, 2015 at 7:46 AM | Reply Ember Branch

This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.

A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.

Loading...